Quarterly ResultMay 6, 2026, 04:07 PM
RxSight Q1 Sales $30.9M, Net Loss $(15.9)M; EPS $(0.38)
AI Summary
RxSight, Inc. reported first-quarter 2026 sales of $30.9 million, an 18.5% decrease year-over-year, largely due to lower Light Delivery Device (LDD) unit volumes. The company posted a net loss of $(15.9) million, or $(0.38) per share, compared to a net loss of $(8.2) million in Q1 2025. Despite the sales decline, gross profit margin improved to 76.1%, driven by a favorable product mix. RxSight maintained its 2026 sales and gross margin guidance but expects operating expenses to be at the high end of the previous range due to strategic growth investments.
Key Highlights
- Q1 2026 sales were $30.9 million, an 18.5% decrease from the prior year.
- Reported a Q1 net loss of $(15.9) million, or $(0.38) per basic and diluted share.
- Gross profit margin for Q1 increased to 76.1% from 74.8% year-over-year.
- Total operating expenses rose to $41.3 million in Q1 2026.
- Sold 27,472 Light Adjustable Lens (LAL) units and 20 Light Delivery Devices (LDDs) in Q1.
- Maintained 2026 sales guidance of $120 million to $135 million and gross margin guidance of 70% to 72%.
- Cash, cash equivalents, and short-term investments totaled $217.9 million as of March 31, 2026.